Kura Oncology(NASDAQ) KURA

Kura Oncology makes medicines that target cancer. Its first approved drug helps adults with a blood cancer. These oral pills treat specific genetic changes in patients.

Precision Cancer Therapies

• KOMZIFTI: FDA-approved oral drug for adults with blood cancers that have returned; net product revenue reached $14.9 million during the first half of 2026.
• Menin Inhibitors: Clinical programs testing drugs that block specific proteins to stop cancer cells from multiplying in leukemia patients.
• Farnesyl Transferase Inhibitors: Targeted therapies such as darlifarnib designed to disrupt growth signals used by kidney and lung cancer cells.
• Metabolic Pipeline: Early-stage candidates being developed to treat diabetes and other heart-related metabolic conditions through protein inhibition.

Recent Strategic Milestones

• Entered a global collaboration with Kyowa Kirin in Nov. 2024 to develop and commercialize ziftomenib for blood cancers.
• Launched commercial sales of its first approved product, KOMZIFTI, in the United States on Nov. 21, 2025.
• Initiated KOMET-017 Phase 3 trials in Sept. 2025 to evaluate treatments in newly diagnosed leukemia patients.
• Dosed the first patient in a Japanese registration-directed clinical trial for ziftomenib in April 2026.
• Announced a new platform study in June 2026 to test darlifarnib across multiple cancer therapy combinations.

How the Company Competes

Kura transformed from a research firm into a commercial-stage organization with its first approved therapy. It uses a partnership model to share domestic profits while leveraging global expertise for international markets.

Key Performance Metrics

• Market capitalization was $974.7 million in Q2 2026, up 92.9% year over year.
• Net product revenue totaled $14.9 million for the six-month period ended June 30, 2026.
• Collaboration revenue was $24.3 million for the first half of 2026, compared to $29.4 million in the prior year period.
• Cash and short-term investments reached $519.0 million as of June 30, 2026.
• The accumulated deficit was $1.3 billion as of June 30, 2026.

Evolution and Strategy

Kura has transitioned from early discovery to a commercial entity with its first FDA-approved therapy. Its growth relies on expanding its flagship drug into earlier treatment lines through large-scale clinical trials and global partnerships.